Dear ISSWSH members,
It is with great excitement that I share the announcement that flibanserin, a drug for hypoactive sexual desire disorder (HSDD) developed by Sprout Pharmaceuticals, was recommended for approval by the FDA Advisory Committee Panel on June 4, 2015.
The International Society for the Study of Women's Sexual Health (ISSWSH), the preeminent scientific organization focused on research, education, and clinical practice of women's sexuality, applauds the FDA's recent announcement of it's upcoming Joint Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee on June 4, 2015.
FDA announced a Public Advisory Committee Meeting to review the approval of flibanserin for hypoactive sexual desire disorder (HSDD) in women on June 4, 2015. Should you wish to submit your written comments or request time at the public microphone, the deadline is a week away. Please find all details in the Federal Register Notice by clicking on this link. - -
Letter from ISSWSH, as response to Op Ed Piece "Nothing Is Wrong WIth Your Sex Drive" in the NY Times.
Click here for the letter. - -
Click here for the letter. - -
The ISSWSH Business Meeting will take place in the Capitol Ballroom A-D of the Sheraton Austin Hotel at the Capitol in Austin, TX on Friday February 20, 2015. The meeting is scheduled for 60 minutes from 5:00 - 6:00 pm.
Click here for the letter. - -